GlassScriptPhysician profile
Mary T Pentel
NPI 1588677058
$54,991.68
in general payments reported to CMS, 2019-2025
47 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $13K · 2021: $5,801 · 2022: $12K · 2023: $1,433 · 2024: $2,530 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,882 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,881.58 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $36,729.22 | 2019-2025 | Aklief, Epsolay, Oracea |
| Merz North America, INC. | $8,340.84 | 2019-2025 | Xeomin |
| Abbvie INC. | $1,242.48 | 2019-2024 | |
| Allergan, INC. | $776.41 | 2019-2022 | |
| Organogenesis INC. | $664.04 | 2020-2025 | Puraply, Novachor, Affinity |
| Janssen Biotech, INC. | $514.87 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $512.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $427.33 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $393.82 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $387.13 | 2019-2023 | |
| Biofrontera INC. | $378.49 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $367.48 | 2019-2023 | Adbry |
| Revance Therapeutics, INC. | $327.61 | 2024-2025 | Daxxify |
| Sebela Pharmaceuticals INC. | $264.55 | 2019-2020 | |
| Incyte Corporation | $245.10 | 2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.96 | 2019-2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $213.00 | 2019 | |
| Almirall LLC | $205.68 | 2019-2025 | Klisyri |
| Genzyme Corporation | $204.01 | 2019-2023 | |
| Amgen INC. | $189.18 | 2019-2023 | Otezla |
| Lilly USA, LLC | $178.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $178.44 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $165.76 | 2021-2025 | Libtayo |
| Strata Skin Sciences, INC. | $163.19 | 2019-2025 | Xtrac |
| Lumenis Be INC | $140.52 | 2024 | Optilight |
| Solta Medical, A Division of Bausch Health US, LLC | $130.02 | 2020-2025 | Clear+Brilliant |
| Dermira, INC. | $129.53 | 2019-2020 | |
| Ucb, INC. | $129.10 | 2021-2024 | Bimzelx |
| Bioventus LLC | $121.81 | 2022-2023 | |
| Dermavant Sciences, INC. | $120.90 | 2023 | Vtama |
| Acelrx Pharmaceuticals, INC. | $117.88 | 2021 | |
| Mimedx Group, INC. | $114.32 | 2024-2025 | |
| Sandoz INC. | $73.04 | 2019 | |
| Sensus Healthcare, INC. | $72.06 | 2021 | |
| Kerecis Limited | $71.62 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Botanix Sb INC | $65.95 | 2025 | Sofdra |
| Misonix INC | $62.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.88 | 2023-2024 | Spevigo |
| Genentech USA, INC. | $46.66 | 2019-2020 | |
| Celgene Corporation | $40.82 | 2019 | |
| Verrica Pharmaceuticals INC. | $40.57 | 2023-2024 | Ycanth |
| Pfizer INC. | $37.58 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $36.52 | 2019 | |
| Epi Health, LLC | $33.95 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $22.47 | 2025 | Spinosad, Natroba |
| Aclaris Therapeutics, INC. | $22.34 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Pentel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.